Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,... see more

Recent & Breaking News (GREY:ATBPF)

Antibe Announces Appointment of Receiver

Business Wire April 24, 2024

Antibe Provides Update on CCAA Proceedings

Business Wire April 19, 2024

Antibe Announces TSX Delisting Review

Business Wire April 16, 2024

Antibe Announces Granting of Initial Order Under Companies' Creditors Arrangement Act

Business Wire April 9, 2024

Canadian Investment Regulatory Organization Trade Resumption - ATE

Canada NewsWire April 9, 2024

Canadian Investment Regulatory Organization Trading Halt - ATE

Canada NewsWire April 9, 2024

Antibe to File an Application for an Initial Order Under Companies' Creditors Arrangement Act

Business Wire April 9, 2024

Antibe Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance

Business Wire April 1, 2024

Antibe to Present Otenaproxesul PK/PD Results at the ASRA Pain Medicine Meeting

Business Wire March 20, 2024

Antibe to Present Otenaproxesul PK/PD Results at the American Academy of Pain Medicine Meeting

Business Wire March 7, 2024

Antibe Announces Unfavorable Decision in Arbitration With Nuance Pharma

Business Wire March 4, 2024

Antibe Reports Q3 2024 Interim Financial and Operating Results

Business Wire February 14, 2024

Antibe Extends Early Warrant Exercise Incentive Program

Business Wire February 1, 2024

OTC Markets Group Announces the 2024 OTCQX Best 50

GlobeNewswire January 18, 2024

Antibe Announces Early Warrant Exercise Incentive Program

Business Wire December 29, 2023

Antibe Therapeutics Announces Amendment to Warrant Terms

Business Wire December 12, 2023

Antibe Reports Q2 2024 Interim Financial and Operating Results

Business Wire November 13, 2023

Antibe Reports PK Results of First Clinical Study of Otenaproxesul's New Formulation

Business Wire November 9, 2023

Antibe Completes First Clinical Study of Otenaproxesul's New Formulation

Business Wire November 1, 2023

Antibe Initiates First Clinical Study of Otenaproxesul's New Formulation

Business Wire October 18, 2023